Literature DB >> 18307245

Emotional speech in Parkinson's disease.

Janine Möbes1, Gregor Joppich, Frank Stiebritz, Reinhard Dengler, Christine Schröder.   

Abstract

Patients with Parkinson's disease (PD) tend to speak monotonously with minor modulation of pitch and intensity. The goal of this study was to find out whether these speech changes can be explained mainly by motor impairment, i.e. akinesia and rigidity of the articulatory apparatus, or whether alterations of emotional processing play an additional role. Sixteen patients with mild PD and 16 healthy controls (HC) were compared. Fundamental frequencies (pitch) and intensities (loudness) were determined as (1) maximal upper and lower values achieved in nonemotional speech (phonation capacity), (2) upper and lower values used when speaking "Anna" in emotional intonation (neutral, sad, happy) as requested (production task), or (3) when imitating a professional speaker (imitation task). Although groups did not significantly differ in their phonation capacity, patients showed a significantly smaller pitch and intensity range than HC in the production task. In the imitation task, however, ranges were again similar. These results suggest that alterations of emotional processing contribute to speech changes in PD, especially regarding emotional prosody, in addition to motor impairment. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18307245     DOI: 10.1002/mds.21940

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  11 in total

1.  Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy.

Authors:  Jan Rusz; Roman Cmejla; Hana Růžičková; Jiří Klempíř; Veronika Majerová; Jana Picmausová; Jan Roth; Evžen Růžička
Journal:  J Neural Transm (Vienna)       Date:  2012-07-08       Impact factor: 3.575

2.  Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease.

Authors:  Sabine Skodda; Wenke Visser; Uwe Schlegel
Journal:  J Neural Transm (Vienna)       Date:  2009-12-12       Impact factor: 3.575

3.  Assessment of prosodic communicative efficiency in Parkinson's disease as judged by professional listeners.

Authors:  Heidi Martens; Gwen Van Nuffelen; Patrick Cras; Barbara Pickut; Miet De Letter; Marc De Bodt
Journal:  Parkinsons Dis       Date:  2011-09-28

4.  Pathomechanisms and compensatory efforts related to Parkinsonian speech.

Authors:  Christiane Arnold; Johannes Gehrig; Suzana Gispert; Carola Seifried; Christian A Kell
Journal:  Neuroimage Clin       Date:  2013-10-31       Impact factor: 4.881

5.  Progression of voice and speech impairment in the course of Parkinson's disease: a longitudinal study.

Authors:  S Skodda; W Grönheit; N Mancinelli; U Schlegel
Journal:  Parkinsons Dis       Date:  2013-12-10

6.  Speech and communication in Parkinson's disease: a cross-sectional exploratory study in the UK.

Authors:  Maxwell S Barnish; Simon M C Horton; Zoe R Butterfint; Allan B Clark; Rachel A Atkinson; Katherine H O Deane
Journal:  BMJ Open       Date:  2017-05-29       Impact factor: 2.692

7.  Self-reported and experimentally induced self-disgust is heightened in Parkinson's disease: Contribution of behavioural symptoms.

Authors:  Marianna Tsatali; Paul G Overton; Ana B Vivas
Journal:  PLoS One       Date:  2019-10-16       Impact factor: 3.240

8.  Investigating emotions in Parkinson's disease: what we know and what we still don't know.

Authors:  Igor Sotgiu; Maria L Rusconi
Journal:  Front Psychol       Date:  2013-06-10

9.  Independence of valence and reward in emotional word processing: electrophysiological evidence.

Authors:  Laura Kaltwasser; Stephanie Ries; Werner Sommer; Robert T Knight; Roel M Willems
Journal:  Front Psychol       Date:  2013-04-08

10.  Autonomic factors do not underlie the elevated self-disgust levels in Parkinson's disease.

Authors:  Vasileia Aristotelidou; Marianna Tsatali; Paul G Overton; Ana B Vivas
Journal:  PLoS One       Date:  2021-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.